- https://bit.ly/31xbIr8

• Understand the pathology of psoriatic disease, its manifestations and related comorbidities, indicating why it’s important to treat the disease to target.
• Develop strategies for improving psoriatic disease health outcomes through management and treatment options which includes patient lifestyle changes to current and emerging pharmacologic therapies.
• Select appropriate therapies for moderate to severe psoriatic disease based on current evidence for efficacy, safety and adherence, particularly with regard to comorbidities.

PsoundBytes: One Plaque Matters: The Impact of Cardiovascular and Psoriatic Disease

• Nehal Mehta, MD

• The National Psoriasis Foundation designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hear the latest news about the association between psoriasis and cardiovascular disease - from lipoproteins and inflammation to the metabolic bin, and how treatments can impact health risks from cardiologist Dr. Nehal Mehta, Chief of the Section of Inflammation and Cardiometabolic Diseases at the National Institutes of Health in Bethesda, MD.

Andi Agnew, NPF Staff/Planning Committee, has disclosed no financial relationships with any commercial interests.

Nehal Mehta, MD has disclosed a relevant financial relationship with a commercial interest in the last 12 months:

• Amgen, Lilly, Leo Pharma - Contracted Research
• Abbvie, Celgene, Janssen, Novartis - Contracted Research

• The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

0 %

4/6/2020